Free Trial

Danske Bank A S Sells 247,694 Shares of Merck & Co., Inc. $MRK

Merck & Co., Inc. logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Danske Bank cut its Merck stake by 11.5%, selling 247,694 shares in the third quarter. It retained 1.90 million shares, valued at about $276.7 million at quarter-end.
  • Merck reported quarterly adjusted earnings of $2.49 per share, beating the $2.09 analyst consensus, while revenue rose 4.7% year over year to $18.09 billion.
  • European regulators recommended expanding the uses of ENFLONSIA and WELIREG in the EU, but European Commission approval is still required before the recommendations can take effect.
  • Five stocks we like better than Merck & Co., Inc..

Danske Bank A S lessened its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 11.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,904,328 shares of the company's stock after selling 247,694 shares during the quarter. Merck & Co., Inc. accounts for approximately 0.5% of Danske Bank A S's holdings, making the stock its 28th largest holding. Danske Bank A S owned 0.08% of Merck & Co., Inc. worth $276,718,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in MRK. BlackRock Inc. raised its stake in shares of Merck & Co., Inc. by 0.5% during the 2nd quarter. BlackRock Inc. now owns 226,999,837 shares of the company's stock worth $29,169,479,000 after purchasing an additional 1,073,507 shares in the last quarter. State Street Corp raised its stake in Merck & Co., Inc. by 0.9% in the second quarter. State Street Corp now owns 120,413,256 shares of the company's stock valued at $15,573,754,000 after buying an additional 1,087,583 shares during the period. Wellington Management Group LLP raised its stake in Merck & Co., Inc. by 2.3% in the 2nd quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company's stock valued at $11,083,033,000 after acquiring an additional 1,934,312 shares during the period. Fisher Asset Management LLC increased its holdings in shares of Merck & Co., Inc. by 8.3% in the third quarter. Fisher Asset Management LLC now owns 41,699,432 shares of the company's stock valued at $6,059,345,000 after purchasing an additional 3,183,169 shares during the last quarter. Finally, Bank of America Corp DE increased its holdings in shares of Merck & Co., Inc. by 10.5% in the first quarter. Bank of America Corp DE now owns 30,774,221 shares of the company's stock valued at $3,701,831,000 after purchasing an additional 2,919,780 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors.

Merck & Co., Inc. Trading Up 0.5%

Shares of NYSE:MRK traded up $0.79 during trading on Friday, reaching $147.74. The stock had a trading volume of 6,504,320 shares, compared to its average volume of 9,885,298. The firm's fifty day moving average is $146.16 and its 200 day moving average is $128.61. Merck & Co., Inc. has a 52 week low of $91.49 and a 52 week high of $156.92. The stock has a market cap of $364.21 billion, a price-to-earnings ratio of 152.31, a P/E/G ratio of 6.74 and a beta of 0.13. The company has a debt-to-equity ratio of 1.11, a quick ratio of 1.14 and a current ratio of 1.35.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its earnings results on Thursday, October 29th. The company reported $2.49 earnings per share for the quarter, topping analysts' consensus estimates of $2.09 by $0.40. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 3.64%. The business had revenue of $18.09 billion during the quarter, compared to the consensus estimate of $17.33 billion. During the same period in the previous year, the company posted $2.58 earnings per share. The firm's revenue for the quarter was up 4.7% on a year-over-year basis. As a group, equities analysts forecast that Merck & Co., Inc. will post 2.82 EPS for the current fiscal year.

Top Merck & Co., Inc. Stories

These are some of the MRK stories that stood out recently:

  • Positive Sentiment: The EMA’s CHMP recommended expanding ENFLONSIA’s use to help prevent severe RSV lower respiratory tract disease in vulnerable children up to 24 months old, including through their second RSV season. The broader eligible population could support the medicine’s commercial opportunity in Europe. Merck ENFLONSIA CHMP recommendation
  • Positive Sentiment: The CHMP also recommended WELIREG plus lenvatinib for adults with advanced clear-cell renal cell carcinoma after anti-PD-1/PD-L1 treatment. This would extend WELIREG into another treatment setting and expand Merck’s oncology portfolio in Europe. Merck WELIREG CHMP recommendation
  • Neutral Sentiment: Both decisions are CHMP recommendations; European Commission approval is still needed. Any financial contribution will also depend on launch timing, uptake and competition.

Analyst Upgrades and Downgrades

MRK has been the subject of a number of analyst reports. Berenberg Bank lifted their price target on shares of Merck & Co., Inc. from $127.00 to $137.00 and gave the company a "hold" rating in a research report on Friday, September 11th. Guggenheim lifted their target price on Merck & Co., Inc. from $170.00 to $171.00 and gave the company a "buy" rating in a research report on Friday, October 30th. Morgan Stanley dropped their price objective on shares of Merck & Co., Inc. from $179.00 to $177.00 and set an "overweight" rating for the company in a research note on Wednesday, October 7th. Weiss Ratings upgraded Merck & Co., Inc. from a "hold (c-)" rating to a "hold (c)" rating in a research report on Tuesday, August 25th. Finally, DZ Bank cut Merck & Co., Inc. from a "buy" rating to a "hold" rating and set a $153.00 target price for the company. in a report on Tuesday, November 3rd. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $155.74.

View Our Latest Stock Report on MRK

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company's research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.

Further Reading

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Merck & Co., Inc. Right Now?

Before you consider Merck & Co., Inc., you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.

While Merck & Co., Inc. currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines